Drug intelligence / Profile preview

ARC151

Development stage: Preclinical
Lead developer: Third Arc Bio
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ARC151 is a preclinical T-cell engager developed by Third Arc Bio, Inc. It is designed to co-stimulate the T-cell surface glycoproteins CD3 and CD28, aiming to activate the immune system's anti-cancer response. This dual targeting strategy is intended to facilitate a strong anti-cancer immune response while potentially minimizing side effects. The drug's development leverages Adagene's SAFEbody technology, a precision antibody masking platform, to selectively activate the drug's action in the tumor microenvironment. ARC151 is being investigated for the treatment of solid tumors.

Targets

CD3 (T-cell surface glycoprotein CD3)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on ARC151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC151.

Explore the full profile